Keytruda's withdrawn third-line gastric approval (2017-2021)
The FDA granted Merck accelerated approval in 2017 for Keytruda in recurrent gastric or gastroesophageal junction cancer after two prior therapies, based on how much tumors shrank rather than on survival. Confirmatory trials in earlier lines did not deliver the survival benefit the agency expected.
Merck withdrew the third-line gastric indication in the United States in 2021.
The episode made tumor shrinkage an unreliable basis for gastric cancer approval and put the focus on survival endpoints.
Merck is now leading with overall survival in the same disease, after losing an indication there five years ago.
